In another study on patients with advanced NSCLC who received EGFR–TKI treatment, KRAS G12C mutation was identified as a strong negative predictor of therapeutic benefits (Fiala et al., 2013). This evidence concerns the gene KRAS and non-small cell lung carcinoma.